NEW YORK, June 13, 2011 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:
This research service provides an in depth analysis of factors affecting the growth of the U.S. asthma/COPD market over the period 2006-2016. Included is a disease overview, product analysis, total market revenue forecasts, product revenue forecasts, patient forecasts, and market share analysis. The market is segmented by mechanisms of action: anti-inflammatories, bronchodilators, and combination therapies. Major market challenges, drivers, and restraints and identified and discussed. Included are examinations of therapeutic candidates in the asthma/COPD pipeline for phase III.
Table of Contents
C h a p t e r 1
Executive Summary
U.S. Asthma/COPD Market 1-1
Introduction 1-1
C h a p t e r 2
Market Introduction
Research Scope and Methodology 2-1
Scope and Segmentation 2-1
Research Methodology 2-2
Assumptions in Revenue Forecasts: 2-3
Market Overview 2-4
Asthma Disease Overview 2-4
Disease Definition 2-4
Risk Factors 2-4
Disease Classification 2-6
COPD Disease Overview 2-6
Disease Definition 2-6
Risk Factors 2-7
Disease Classification 2-8
Market Engineering Measurements 2-8
Market Age 2-9
Base Year Revenues 2-10
Potential Revenues for 2016 2-10
Base Year Market Growth Rate 2-10
Compound Annual Growth Rate 2-10
Active Market Competitors in Base Year 2-10
Base Year Market Concentration 2-10
Number of New Products in Phase III Trials 2-11
Price Sensitivity 2-11
Patient Forecasts—Asthma 2-11
Patient Forecasts—COPD 2-13
Total Patient Forecasts 2-16
Industry Challenges 2-18
Low Patient Awareness Inhibits Market Size 2-18
Need for Market Specific Expertise Inhibits Entry of New Participants 2-19
Lack of Patient Compliance Hinders Market Growth 2-19
Absence of Effective Treatments Slows Market Growth 2-20
Market Drivers 2-20
Increasing Incidence of Asthma and COPD Drives Market Growth 2-20
Lack of Generic Inhalers on the Market Inflates Prices and Revenue 2-21
Introduction of New Drug Classes Promotes Market Expansion 2-21
Market Restraints 2-21
Adverse Side Effects Deter Patients from Using Medication 2-22
Expected Entry of Generic Products Impedes Revenue Growth 2-23
Bronchodilators Product Analysis 2-23
Short-Acting Bronchodilators Product Analysis 2-23
Xopenex HFA (levalbuterol) 2-24
Long-Acting Bronchodilators Product Analysis 2-25
Foradil Aerolizer (formoterol fumarate) 2-25
Anticholinergics Product Analysis 2-26
Spiriva Handihaler (tiotropium bromide monohydrate) 2-27
Combination Bronchodilators Product Analysis 2-28
Combivent Inhalation Aerosol (albuterol sulfate/iprotropium bromide) 2-28
Anti-Inflammatories Product Analysis 2-29
Inhaled Corticosteroids Product Analysis 2-29
Pulmicort Respules (budesonide) 2-30
Anti-Leukotriene Product Analysis 2-30
Singulair (montelukast sodium) 2-31
Monoclonal Antibodies Product Analysis 2-31
Xolair (omalizumab) 2-32
Combination Therapies Product Analysis 2-33
Combination Therapies Product Analysis 2-33
Advair (fluticasone/salmeterol) 2-33
Pipeline Analysis 2-34
Phase III Pipeline Analysis 2-34
QAB 149 (Indacaterol) 2-35
NVA 237 2-35
QVA 149 2-36
Daxas (roflumilast) 2-36
C h a p t e r 3
Competitive Analysis
Total Market Forecasts 3-1
Revenue Forecasts for Total Asthma/COPD Market 3-1
Revenue Forecasts for Bronchodilators 3-4
Revenue Forecasts for All Bronchodilators 3-4
Revenue Forecasts for Short-Acting Bronchodilators 3-6
Revenue Forecasts for Long-Acting Bronchodilators 3-9
Revenue Forecasts Anticholinergics 3-13
Revenue Forecasts for Combination Bronchodilators 3-16
Revenue Forecasts for Anti-Inflammatories 3-19
Revenue Forecasts for All Anti-Inflammatories 3-19
Revenue Forecasts for Inhaled Corticosteroids 3-21
Revenue Forecasts for Anti-Leukotrienes 3-25
Revenue Forecasts for Monoclonal Antibodies 3-28
Revenue Forecasts for Other Emerging Anti-Inflammatories 3-29
Revenue Forecasts for Combination Therapies 3-31
Revenue Forecasts for Combination Therapies 3-31
Competitive Analysis 3-35
Competitive Structure 3-35
Number and Types of Competitors 3-36
Key End-user Groups 3-36
Competitive Factors 3-36
Market Share Analysis 3-36
Company Market Share 3-36
Product Market Share 3-39
C h a p t e r 4
Appendix
Decision Support Databases 4-1
Mortality Due to Asthma-Bronchitis-and-Emphysema 4-1
Prevalence of Asthma 4-3
Prevalence of COPD 4-5
Mortality Due to Respiratory Disease 4-7
Total Population Over 65 4-10
List of Figures
C h a p t e r 2
Market Introduction
2-1 Asthma/COPD Market:
Asthma Patient Forecasts by Age Bracket (U.S.), 2006-2016 2-12
2-2 Asthma/COPD Market:
COPD Patient Forecasts by Age Bracket (U.S.), 2006-2016 2-14
2-3 Asthma/COPD Market:
Emphysema and Chronic Bronchitis Patient Forecasts (U.S.), 2006-2016 2-15
2-4 Asthma/COPD Market:
Asthma and COPD Patient Forecasts (U.S.), 2006-2016 2-17
2-5 Asthma/COPD Market:
Top Four Industry Challenges (U.S.), 2010-2016 2-18
2-6 Asthma/COPD Market:
Market Drivers Ranked in Order of Impact (U.S.), 2010-2016 2-20
2-7 Asthma/COPD Market:
Major Market Restraints Ranked in Order of Impact (U.S.), 2010-2016 2-22
2-8 Asthma/COPD Market:
Product Analysis for Selected Short-Acting Bronchodilators (U.S.), 2009 2-24
2-9 Asthma/COPD Market:
Product Analysis for Selected Long-Acting Bronchodilators (U.S.), 2009 2-25
2-10 Asthma/COPD Market:
Product Analysis for Selected Anticholinergics (U.S.), 2009 2-27
2-11 Asthma/COPD Market:
Product Analysis for Selected Combination Bronchodilators (U.S.), 2009 2-28
2-12 Asthma/COPD Market:
Product Analysis for Selected Inhaled Corticosteroids (U.S.), 2009 2-29
2-13 Asthma/COPD Market:
Product Analysis for Selected Anti-Leukotriene (U.S.), 2009 2-30
2-14 Asthma/COPD Market:
Product Analysis for Monoclonal Antibodies (U.S.), 2009 2-31
2-15 Asthma/COPD Market:
Product Analysis for Combination Therapies (U.S.), 2009 2-33
2-16 Asthma/COPD Market:
Phase III Pipeline Analysis (U.S.), 2010 2-35
C h a p t e r 3
Competitive Analysis
3-1 Asthma/COPD Market:
Revenue Forecasts (U.S.), 2006-2016 3-1
3-2 Asthma/COPD Market:
Revenue Forecasts by Market Segment (U.S.), 2006-2016 3-3
3-3 Asthma/COPD Market:
Revenue Forecasts for Bronchodilators (U.S.), 2006-2016 3-4
3-4 Asthma/COPD Market:
Revenue Forecasts for Short-Acting Bronchodilators (U.S.), 2006-2016 3-6
3-5 Asthma/COPD Market:
Revenue Forecasts by Product for Short-Acting Bronchodilators (U.S.), 2006-2016 3-7
3-6 Asthma/COPD Market:
Revenue Forecasts for Long-Acting Bronchodilators (U.S.), 2006-2016 3-10
3-7 Asthma/COPD Market:
Revenue Forecasts by Product for Long-Acting Bronchodilators (U.S.), 2006-2016 3-11
3-8 Asthma/COPD Market:
Revenue Forecasts for Anticholinergics (U.S.), 2006-2016 3-13
3-9 Asthma/COPD Market:
Revenue Forecasts by Product for Anticholinergics (U.S.), 2006-2016 3-15
3-10 Asthma/COPD Market:
Revenue Forecasts for Combination Bronchodilators (U.S.), 2006-2016 3-16
3-11 Asthma/COPD Market:
Revenue Forecasts by Product for Combination Bronchodilators (U.S.), 2006-2016 3-18
3-12 Asthma/COPD Market:
Revenue Forecasts for Anti-Inflammatories (U.S.), 2006-2016 3-20
3-13 Asthma/COPD Market:
Revenue Forecasts for Inhaled Corticosteroids (U.S.), 2006-2016 3-21
3-14 Asthma/COPD Market:
Revenue Forecasts by Product for Inhaled Corticosteroids (U.S.), 2006-2016 3-23
3-15 Asthma/COPD Market:
Revenue Forecasts for Anti-Leukotrienes (U.S.), 2006-2016 3-25
3-16 Asthma/COPD Market:
Revenue Forecasts by Product for Anti-Leukotrienes (U.S.), 2006-2016 3-27
3-17 Asthma/COPD Market:
Revenue Forecasts for Monoclonal Antibodies (U.S.), 2006-2016 3-28
3-18 Asthma/COPD Market:
Revenue Forecasts for Other Emerging Anti-Inflammatories (U.S.), 2006-2016 3-30
3-19 Asthma/COPD Market:
Revenue Forecasts for Combination Therapies (U.S.), 2006-2016 3-32
3-20 Asthma/COPD Market:
Revenue Forecasts by Product for Combination Therapies (U.S.), 2006-2016 3-33
3-21 Asthma/COPD Market:
Competitive Structure (U.S.), 2009 3-35
3-22 Asthma/COPD Market:
Company Market Share by Revenues (U.S.), 2009 3-37
3-23 Asthma/COPD Market:
Company Market Share by Revenues (U.S.), 2016 3-38
3-24 Asthma/COPD Market:
Product Market Share by Revenues (U.S.), 2009 3-39
3-25 Asthma/COPD Market:
Product Market Share by Revenues (U.S.), 2016 3-40
C h a p t e r 4
Appendix
4-1 Decision Support Database:
Mortality due to Asthma, Bronchitis and Emphysema (World), 2002-2012 4-1
4-2 Decision Support Database:
Prevalence of Asthma in Million (World), 2002-2012 4-3
4-3 Decision Support Database:
Population with COPD in '000 (World), 2002-2012 4-5
4-4 Decision Support Database:
Mortality due to Respiratory Disease in '000 (World), 2002-2012 4-8
4-5 Decision Support Database:
Population 65 Plus in Million (World), 2004-2014 4-10
List of Charts
C h a p t e r 2
Market Introduction
2.1 Asthma/COPD Market:
Market Segmentation (U.S.), 2010 2-2
2.2 Asthma/COPD Market:
Market Engineering Measurements (U.S.), 2009 2-9
2.3 Asthma/COPD Market:
Asthma Patient Forecasts by Age Bracket (U.S.), 2006-2016 2-12
2.4 Asthma/COPD Market:
COPD Patient Forecasts by Age Bracket (U.S.), 2006-2016 2-14
2.5 Asthma/COPD Market:
Emphysema and Chronic Bronchitis Patient Forecasts (U.S.), 2006-2016 2-16
2.6 Asthma/COPD Market:
Asthma and COPD Patient Forecasts (U.S.), 2006-2016 2-17
C h a p t e r 3
Competitive Analysis
3.1 Asthma/COPD Market:
Revenue Forecasts (U.S.), 2006-2016 3-2
3.2 Asthma/COPD Market:
Market Revenue Forecasts by Segment (U.S.), 2006-2016 3-3
3.3 Asthma/COPD Market:
Revenue Forecasts for Bronchodilators (U.S.), 2006-2016 3-5
3.4 Asthma/COPD Market:
Revenue Forecasts for Short-Acting Bronchodilators (U.S.), 2006-2016 3-7
3.5 Asthma/COPD Market:
Revenue Forecasts by Product for Short-Acting Bronchodilators (U.S.), 2006-2016 3-8
3.6 Asthma/COPD Market:
Revenue Forecasts for Long-Acting Bronchodilators (U.S.), 2006-2016 3-10
3.7 Asthma/COPD Market:
Revenue Forecasts by Product for Long-Acting Bronchodilators (U.S.), 2006-2016 3-12
3.8 Asthma/COPD Market:
Revenue Forecasts for Anticholinergics (U.S.), 2006-2016 3-14
3.9 Asthma/COPD Market:
Revenue Forecasts by Product for Anticholinergics (U.S.), 2006-2016 3-15
3.10 Asthma/COPD Market:
Revenue Forecasts for Combination Bronchodilators (U.S.), 2006-2016 3-17
3.11 Asthma/COPD Market:
Revenue Forecasts by Product for Combination Bronchodilators (U.S.), 2006-2016 3-18
3.12 Asthma/COPD Market:
Revenue Forecasts for Anti-Inflammatories (U.S.), 2006-2016 3-20
3.13 Asthma/COPD Market:
Revenue Forecasts for Inhaled Corticosteroids (U.S.), 2006-2016 3-22
3.14 Asthma/COPD Market:
Revenue Forecasts by Product for Inhaled Corticosteroids (U.S.), 2006-2016 3-23
3.15 Asthma/COPD Market:
Revenue Forecasts for Anti-Leukotrienes (U.S.), 2006-2016 3-26
3.16 Asthma/COPD Market:
Revenue Forecasts by Products for Anti-Leukotrienes (U.S.), 2006-2016 3-27
3.17 Asthma/COPD Market:
Revenue Forecasts for Monoclonal Antibodies (U.S.), 2006-2016 3-29
3.18 Asthma/COPD Market:
Revenue Forecasts for Other Emerging Anti-Inflammatories (U.S.), 2006-2016 3-30
3.19 Asthma/COPD Market:
Revenue Forecasts for Combination Therapies (U.S.), 2006-2016 3-32
3.20 Asthma/COPD Market:
Revenue Forecasts by Products for Combination Therapies (U.S.), 2006-2016 3-34
3.21 Asthma/COPD Market:
Company Market Share by Revenues (U.S.), 2009 3-37
3.22 Asthma/COPD Market:
Company Market Share by Revenues (U.S.), 2016 3-39
3.23 Asthma/COPD Market:
Product Market Share by Revenues (U.S.), 2009 3-40
3.24 Asthma/COPD Market:
Product Market Share by Revenues (U.S.), 2016 3-41
To order this report:
Drug and Medication Industry: U.S. Asthma/COPD Market
Drug and Medication Business News
Check our Company Profile, SWOT and Revenue Analysis!
Contact Nicolas Bombourg
Reportlinker
Email: [email protected]
US: (805)652-2626
Intl: +1 805-652-2626
SOURCE Reportlinker
Share this article